Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) EBIT : $-2.26 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals EBIT?

Merrimack Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-0.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.26 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Merrimack Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2024 was -1,375.84%. Merrimack Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Merrimack Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 11.09%.

Merrimack Pharmaceuticals EBIT Historical Data

The historical data trend for Merrimack Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals EBIT Chart

Merrimack Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-21.21

-5.01

-2.62

-2.17

-2.18

Merrimack Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-0.59	-0.57	-0.53	-0.49	-0.67

Competitive Comparison of Merrimack Pharmaceuticals's EBIT

For the Biotechnology subindustry, Merrimack Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merrimack Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Merrimack Pharmaceuticals's EV-to-EBIT falls into.

Merrimack Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.26 Mil.

Merrimack Pharmaceuticals (NAS:MACK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Merrimack Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-2.676 * ( 1 - 0% )	/	( (0.195	+	0.19400000000002)	/ 2 )
=	-2.676	/	0.19450000000001
=	-1,375.84 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	19.188	-	0.25	-	( 18.875	-	max(0, 0.441	-	19.184	+	18.875	))
=	0.195

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	244.322	-	22.481	-	( 244.11	-	max(0, 22.672	-	244.319	+	244.11	))
=	0.19400000000002

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Merrimack Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.676	/	( ( (0 + max(-0.132, 0))	+	(0 + max(-22.463, 0)) )	/	2 )
=	-2.676	/	( ( 0	+	0 )	/	2 )
=	-2.676	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.309)	-	(0.25	+	0	+	0.191)
=	-0.132

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.20899999999997)	-	(22.481	+	0	+	0.191)
=	-22.463

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Merrimack Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-2.259	/	-20.362
	=	11.09 %

Merrimack Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.merrimack.com

Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

Executives

Eric Andersen	director, other: See Remarks	1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker	director, officer: President	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy	director, other: See Remarks	60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic	director	2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p.	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc	other: See Remarks	5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc.	10 percent owner, other: See Explanation of Responses	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107